Introduction
============

Oral cancer is the most common neoplasm of head and neck region, being squamous cell carcinoma (OSCC) the most frequent histological type. Although the oral cavity region is accessible to visual examination, oral cancer is still diagnosed at advanced stage when signs and symptoms are already present [@B1]. In contrast, in early stages oral malignant lesions are usually benign in appearance and, as they are often asymptomatic, patients tend to depreciate the small signs [@B2]. When oral cancer is detected at early stages, 5-year survival rate is around 90%, whereas in later stages the survival rate decreases to about 30% [@B3]. As so, clinical staging at the time of diagnosis is of utmost importance and can be used as a predictor of recurrence and mortality in oral cancer patients. On the other hand, the treatment of advanced tumors is frequently very mutilating, leading to visible deformations which, in turn, results in social stigmatization, speech disabilities and nutrition problems [@B4]-[@B6]. Additionally, the behavior of OSCC is difficult to predict using solely conventional clinical and histopathological parameters [@B7]. Accurate prognostic biomarkers should have immediate applicability on the clinical set, allowing to select patients for more effective tailored treatment strategies and conceivably for shorter monitoring programs. Tissue biopsy with histological assessment remains the gold standard in oral diagnosis, which needs a trained health-care provider, and is considered invasive, painful, expensive and time consuming [@B8]. Nowadays, several advancements have been made in the development of potentially useful diagnostic tools at the clinical and molecular level for early detection of oral cancer and its relapses, such as exfoliative cytology (consisting in cell collection from mucosal surfaces by scrapping or brushing) that presents as advantages the fact that it is painless, non-invasive, easy to perform and can be repeated several times to diagnose and follow-up the patients [@B9], [@B10]. Even so, non-invasive tools have not yet proved their value in clinical routine since they were unable to reduce the problem of late diagnosis [@B11].

In this study we identified a specific genomic and epigenetic profile associated with OSCC survival and risk of relapse/metastasis development and, consequently, with patients\' prognosis. This genomic signature was validated using TCGA data, and may contribute for accurately stratifying patients for personalized clinical management. Additionally, we developed a noninvasive approach of identifying this genomic and epigenetic signature by evaluating in tumor samples and in cells scrapped from the tumor surface of the same OSCC patients through Methylation-Specific Multiplex Ligation-dependent Probe Amplification (MS-MLPA) technique. However, this noninvasive approach only showed good agreement for *CDKN2A* promoter methylation.

Materials and methods
=====================

Study population
----------------

The study protocol was approved by the Committee on Ethics in Research of the Faculty of Medicine of the University of Coimbra. All patients provided their written consent to participate in the study after being informed about the research purposes, following the regulations in the Declaration of Helsinki.

The study cohort includes tumor tissue, Tissue from surgery resection margin (macroscopically tumor-free tissue) and exfoliated cells, scrapped from the tumor surface, of 49 OSCC patients who underwent tumor resection. The surface of tumor, before surgery, was gentle scrapped with a blunt instrument to obtain exfoliated neoplastic cells. The material obtained was then taken in a falcon tube with phosphate buffered saline buffer and stored at 4ᵒC until DNA extraction, which was performed within one week after collection. The tissue samples were snap-frozen in liquid nitrogen within 30 min after resection and stored at -80ºC until use. The patients were recruited between October 2010 and January 2016 from the Maxillofacial Surgery Unit of the Coimbra Hospital and University Centre, CHUC, EPE, Portugal. Diagnosis and staging were performed in accordance with the American Joint Committee on Cancer TNM staging system. The participants in this study answered a survey regarding lifestyle and risk factors for upper aerodigestive tract malignancies, including alcohol and tobacco consumption. Patients were followed-up through hospital revisits during routine clinical appointments. The follow-up periods ranged from 1 to 63 months. Details of our study cohort are listed in Table [1](#T1){ref-type="table"}. For the control group of tissue samples, gingival tissues from 16 healthy donors (6 males and 10 females, with ages ranging from 18 to 81 years) subjected to wisdom teeth removal were used. For the control group of tumor exfoliated cell samples, cells acquired by scrapping the oral surface of 14 healthy donors (4 males and 10 females, with ages ranging from 23 to 60 years) were used.

DNA extraction, HPV typing and MS-MLPA
--------------------------------------

DNA from fresh frozen tissues of patients and controls were extracted using a High Pure PCR Template Preparation Kit (Roche GmbH, Mannheim, Germany), according to the manufacturer\'s instructions. The DNAs were quantified by UV spectrophotometric analysis using a Nanodrop 1000 Spectrophotometer (Thermo Scientific, USA). All tumor tissue samples were analyzed for HPV infection as previous described [@B12], [@B13].

MS-MLPA analyses were performed using MS-MLPA probe set ME002 (MRC-Holland, Amsterdam, The Netherlands), which can simultaneously detect copy number alterations (CNAs) in 38 tumor suppressor genes and aberrant methylation patterns in a subset of 25 of these genes (Figure [1](#F1){ref-type="fig"}). All MS-MLPA reactions were performed according our previous work [@B14]. Three controls selected from the previously analyzed control group of 16 from tissue samples and 11 from exfoliated cells, without CNAs and methylation values below 20%, as well as a negative control (without DNA), were always included in each MS-MLPA assay. Binning of the raw data and comparative analyses were performed using Coffalyser.NET software. For each probe we determined the specific cutoff values for gain and loss, using 95% confidence intervals as determined on non-cancer subjects. A copy number gain was scored when a value exceeded 1.2 and a copy number loss was scored when a value was lower than 0.8. We considered a gene promoter as methylated when the methylation dosage ratio was ≥ 0.20, which means that at least 20% of the DNA was methylated. These cut-off values were based in our previous works [@B12]-[@B14].

Validation cohort from TCGA data portal
---------------------------------------

Copy number data obtained by SNP array and patients\' clinical data of 314 OSCC were downloaded from the TCGA Data Portal, available at <https://tcga-data.nci.nih.gov/tcga/>, (accessed on the 23rd October 2015). The available copy number data was Level 3 data. The clinical-pathologic features of the validation cohort are listed in Table [2](#T2){ref-type="table"}.

Statistical analysis
--------------------

Data analysis was essentially divided in three parts: one focusing the relationship between genetic/epigenetic data and survival information, another attempting to obtain a genetic and epigenetic biomarker for relapses or metastases and, finally, a part regarding agreement between tissue samples and scrapped cells of the tumor surface.

Copy number and methylation data was obtained for tumor and non-tumor cells thus comparing the same genes between the two tissues, thus aiming to enlighten which genes are really contributing to tumoral features. This comparison was performed resorting to the difference between the entropy [@B15] computed for each gene, and genes that showed larger differences were considered to be significant to explain dissimilarities between tumor and non-tumor cells. Afterwards a factorial analysis, with two factors, was performed aiming at achieving a smaller group of genes and the relationship of them to each factor and to each observation. Additionally, a cluster analysis (two step method) was carried out and two different groups of observations were found. Finally, survival data was compared between these two groups using Kaplan-Meyer analysis and the Log Rank test.

In order to achieve a form of estimating the risk of relapses or metastases a classification algorithm was implemented. Variable importance plots based on Gini index [@B16] were employed to select the most informative genes and a Random Forest method was implemented with a k-fold cross validation technique.

Agreement between genetic data coming from tissues samples and scrapped cells was computed using Kappa statistics for each gene.

Statistical analysis was performed using R statistics platform (R version 3.3.2) and Matlab (R2016b, Matworks™). The statistical level of significance adopted was 0.05.

Results
=======

Genomic signature associated with OSCC survival
-----------------------------------------------

We evaluated whether the genetic differences between the tumor and non-tumor tissue samples could be used as survival predictors using entropy differences between the results of CNAs for the genes analyzed in these two kinds of samples. Firstly, we reduced data by selecting only the genes presenting a difference higher than 50%. The selected genes were: *ATM, BRCA2, CADM1, CASR, CD44, CDH13, CDK6, CREM, ESR1, KLLN, MGMT, MLH3, PAX5, PAX6, PTEN, RARB, RB1, THBS, TP73* and *WT1* (figure [2](#F2){ref-type="fig"}A).

Applying factorial and clusters analysis, we reached a division of our cohort into two clusters with a Cronbach alpha of 0.781 (internal consistency) and a silhouette Coefficient of 0.7 (cluster consistency). The genes that most contribute for this division were *ATM*, *CASR*, *TP73*, *CADM1*, *RARB*, *CDH13*, *PAX5* and *RB1*.

Cluster 1 presented a proportion of 71% (35 patients) and cluster 2 of 29% (14 patients).

The genomic signature of these two clusters is different, cluster 1 did not presented CNA in the selected genes and cluster 2 presented gains and losses in these genes (figure [2](#F2){ref-type="fig"}B).

Kaplan-Meier curves for the two clusters, considering cluster 1 with all patients without CNAs for the selected genes and cluster 2 with patients that have at least one gene with CNA were performed. We observed that the average survival for cluster 1 was 48.2 months (CI95% \[39.5; 56.9\]) whereas for cluster 2 was 40.9 months (CI95% \[25.2; 56.6\]) (figure [3](#F3){ref-type="fig"}A). We did not reach statistical significance (Log-Rank: p=0.243).

A validation of these results using TCGA data was performed, including 58 patients in cluster 1 and 254 in cluster 2. In this validation cohort, the average survival for cluster 1 was 98.6 months and for cluster 2 was 79.9 months (figure [3](#F3){ref-type="fig"}B). In this validation cohort it was possible to observe 18.7 months of survival difference between the two clusters, which is higher than those observed in our cohort (7.3 months). Despite, this clinical relevant difference, we did not find statistical significance (Log-Rank: p=0.377).

Considering the observed clinical relevant difference in survival of both clusters and the absence of statistical significance, we decided to joint both databases (our database from Portuguese patients and database from TCGA) in order to try maximizing the observed differences and enlarge the number of patients. In this joint database the number of patients in cluster 1 was 93 and in cluster 2 was 268. The average survival for cluster 1 was 100 months and for cluster 2 was 77.8 months (data not shown). This joint database showed a difference of 22.2 months in the survival of both clusters. Despite this meaningful survival difference statistical significance was not reached (Log-Rank: p=0.167).

We also researched the effect of tumor stage in the survival, so we considered in this joint database, tumor stage I+II and tumor stage III + IV. Considering tumor stage I+II, Kaplan-Meier curves for the two clusters, cluster 1 with 37 patients and cluster 2 with 74 patients, showed that the average survival for cluster 1 was 135.4 months and for cluster 2 was 80.0 months (figure [4](#F4){ref-type="fig"}A). Patients with tumor stage I+II with and without CNAs (cluster 1 and 2) in the selected genes, exhibited a marginal statistical significance difference (Log-Rank: p=0.049) of 55.4 months in the survival of both clusters.

Considering tumor stage III+IV, Kaplan-Meier curves for the two clusters, cluster 1 with 55 patients and cluster 2 with 187 patients, showed that the average survival for cluster 1 was 84.9 months and for cluster 2 was 71.0 months (figure [4](#F4){ref-type="fig"}B). We verified 13.9 months of difference in survival between these clusters; however, we did not reach statistical significance (Log-Rank: p=0.809).

The distribution of patients\' age is very similar in both clusters, which do not constitute a bias in the observed statistical significance survival differences.

Epigenetic signature associated with OSCC survival
--------------------------------------------------

We evaluated whether the epigenetic differences between the tumor and non-tumor tissue samples could be used as survival predictors using entropy differences between the results of gene promoter methylation in these two kinds of samples. We reduced the data, selecting only the genes with a difference higher than 50%. The selected genes were: *ATM, BRCA1, BRCA2, CADM1, CDKN2A, CHFR, ESR1, GATA5, MGMT, PAX5, PAX6, TP53* and*TP73* (figure [5](#F5){ref-type="fig"}A).

Applying factorial and clusters analysis with these selected genes, we reached a division of our cohort into two clusters with a Cronbach alpha of 0.718 and a silhouette Coefficient of 0.7. The cluster 1 presented a proportion of 57% with 28 patients and the cluster 2 of 43% with 21 patients.

The epigenetic profile of these two clusters is different. We observed that cluster 1 did not present any gene promoter methylation and cluster 2 presented methylation in these genes (figure [5](#F5){ref-type="fig"}B).

Kaplan-Meier curves for the two clusters were performed, being 47.8 months the average survival of cluster 1 (CI95% \[38.5; 57.1\]) and 44.8 months of cluster 2 (CI95% \[31.8; 57.7\]) (figure [6](#F6){ref-type="fig"}). We did not reach statistical significance (Log-Rank: p=0.330).

Validation using TCGA data was not done because methylation data is not comparable with our own data.

Genomic and epigenetic signatures associated with OSCC relapse/metastasis risk
------------------------------------------------------------------------------

Random Forest model using CNA and gene promoter methylation results to search biomarkers with capability of predicting the relapse/metastases development risk in our OSCC cohort was performed. For CNA, we verified that a set of eight genes has the power to discriminate between patients that developed relapse/metastases during clinical follow up from those without recurrence. The genomic signature with potential to perform this discrimination comprises the following genes: *BRCA1, CDKN2A, CHFR, GATA5, PYCARD, STK11, TP53* and *VHL* (figure [7](#F7){ref-type="fig"}A). We did not reach statistical significance.

A validation of genomic results using TCGA data was performed, but we did not find statistical significance (data not shown).

For gene promoter methylation, we verified that a set of six genes has the power to discriminate between patients that developed relapse/metastases during clinical follow up from those without recurrence.

The epigenetic signature with potential to perform this discrimination comprises the following genes: *CADM1, GATA5, KLNN, MSH6*, *PAX5* and *WT1* (figure [7](#F7){ref-type="fig"}B).

We did not reach a statistical significance.

Agreement between results obtained from tumor tissue samples and scrapped cells of the tumor surface
----------------------------------------------------------------------------------------------------

Evaluation of *CDKN2A* gene promoter methylation status in both tumor tissue and scrapped cells exhibited a total agreement, *Kappa* = 1 (figure [8](#F8){ref-type="fig"}A). From all analyzed genes, in our cohort only the promoter methylation status of *CDKN2A* gene can be assessed using a non-invasive approach with the same result as in the tumor tissue.

For the overall copy number alterations (0.1568929 IC95% \[0.0764; 0.2368\]) and methylation status (0.005028447 IC95% \[-0.0872; 0.1150\]) of the analyzed genes in the tumor tissue and in the scrapped cells (figure [8](#F8){ref-type="fig"} A, B) we observed a reduced agreement.

Discussion
==========

Using a clinically well characterized OSCC cohort, followed during 1 to 63 months, we identified a specific genomic and epigenetic signature associated with survival and risk of metastasis/relapse development during/after treatment. Nowadays we are witnessing an explosion in the knowledge of biological markers related to pathogenesis and progression of OSCC, which might emerge as a possibility to complement the selection of patients to more aggressive treatment modalities. Several chromosomal regions and genes have been pointed out as potential biomarkers for predicting clinical outcome and as therapeutic targets [@B17]-[@B19]. However, single markers have proved insufficient predictive power, so, no biomarker was yet translated to clinical practice [@B20]. Our study gathers novelty since we identified and validate in an independent OSCC cohort a specific set of genes that can predict the patients\' prognosis, with great impact in the survival of the patients. Copy number alterations in *ATM, CASR, TP73, CADM1, RARB, CDH13, PAX5*, *RB1* genes and *GATA5, PAX6, CADM1* and *CHFR* promoter methylation were shown to be associated with worse patient survival in our OSCC patients. Copy number alterations in *BRCA1, CDKN2A, CHFR, GATA5, PYCARD, STK11, TP53, VHL* genes and *GATA5, CADM1, KLNN, MSH6, PAX5* and *WT1* promoter methylation were shown to be associated with development of metastasis/relapses during or after treatment of our OSCC patients. These genomic signatures were validated in a geographically separated cohort (from TCGA database), reinforcing their potential for clinical application, since they were associated with differences in patient survival around 20 months and more than 50 months if we considered only tumor stage I+II. The presence of these set of genes with copy number alterations could guide the clinical management of OSCC patients, indicating which patients have a better prognosis and also which patients must be monitored in closer follow up or should have an intensification of therapy due to the major risk of metastasis/relapse.

Focusing on the individual gene members of the genomic and epigenetic signatures related to survival and metastasis/relapse risk, we see that these genes are highly relevant to OSCC disease. Chief among them is *TP53* gene, in which aberrations are the most frequent molecular events in human cancers. This gene encodes the p53 protein, which is involved in many key events in the cell like regulation of cell cycle and glucose metabolism in cancer cells, DNA-repair, apoptosis, and senescence, which are induced by various stress signals, including DNA-damage and inflammation [@B21], [@B22]. Another gene is *CDKN2A,* in which inactivation was found in 57% of HPV-negative head and neck cancer [@B23]. This gene regulates cell cycle progression by blocking the activity of *CCND1* and its associated kinases, CDK6 and CDK4, which phosphorylate and inactivate the tumor suppressor *RB1* [@B24], [@B25]. Patients that harbor simultaneous amplified *CCND1* and deleted *CDKN2A* presented worse prognosis [@B24]. *BRCA1* overexpression in leukoplakia followed by subsequent underexpression in tongue squamous cell carcinoma was also already described [@B26].*CADM1* downregulation through epigenetic silencing or loss of heterozygosity is related to tumor cell invasion and metastatic potential [@B27], [@B28]. *ATM* plays a role in maintaining genome integrity, being its aberrant promoter methylation linked to lost or greatly diminished expression of several tumor suppressors, namely *BRCA1* [@B29], *CDKN2A* [@B30] and *VHL* [@B31]. *ATM* promoter hypermethylation showed a significant correlation with decreased overall OSCC patient survival [@B32]. We previously reported the association of *MSH6* and *GATA5* promoter methylation with OSCC worse prognosis, being the later gene also significantly associated with shorter survival rate [@B14]. *PAX5* promoter methylation was considered useful to identify patients at high risk of locoregional recurrence, after surgical treatment [@B33].

Even with some limitations, such as, the different platform used to obtain the genomic results (MS-MLPA in our study cohort and SNP-microarray in TCGA cohort) and also the different clinical follow-up frame time of the two cohorts, our results were in general validated in this larger and geographical distinct cohort (from TCGA database). This validation proves the clinical relevance of the identified signatures for OSCC patients. The reduced follow-up time of our patients (1-63 months) and also the junction of two databases with different patients\' follow-up time could explain the absence of survival statistical significance results; nevertheless, the survival difference between the two identified clusters is clear, representing a huge difference in the life time of these patients. Considering the genomic signature to predict the risk of relapses/ metastases, the absence of statistical significance in both cohorts could be due to the reduced number of patients that developed metastases and relapses during the time of follow-up.

Screening oral cancer implies searching oral potentially malignant and cancerous/recurrence lesions, typically before symptoms occur in people belonging to groups of risk. In 2005 Bremmer et al [@B9] showed that the Multiplex Ligation-dependent Probe Amplification (MLPA) technique is suitable for detection of genetic alterations in noninvasive samples, opening the door to improve the early diagnostic of oral potential malignant lesions. Four years later, the same group [@B34] compared the results from exfoliated cells and oral lesions biopsies of the same patients showing a high sensitive rate of this noninvasive technique. However, up to now, this technique was not validated, being still a promise for clinical practice without evidence of a truly practical application. We showed in our cohort that using MS-MLPA technique we could only evaluate the *CDKN2A* gene promoter methylation status with same result either in scrapped cells from surface of tumor or in tumor tissue. The major limitation of these non-invasive samples could be the admixture with normal cells which hampers the detection of genetic and epigenetic alterations of tumor cells. Further studies regarding the collection of these non-invasive samples and also the technologies used to perform the molecular evaluations are needed, since in this moment this non-invasive methodology is not reliable for cancer detection.

Conclusions
===========

Our results suggest the involvement of a specific set of genes that together has the ability to predict the patients\' prognosis. The proposed genomic and epigenetic signatures include genes that individually were already related to OSCC and together proved to be associated to survival and risk of metastasis/relapse development. These findings are of clinical relevance since accurate prognostic biomarkers are still urgently needed in the clinical management of OSCC patients. Our genomic signatures were validated in a larger and geographically separate cohort, from the TCGA database, which reinforce their strength to future biomarker-driven clinical trials. We obtained the same result from *CDKN2A* gene promoter methylation status either in scrapped cells from the surface of tumor or in tumor tissue. Non-invasive methodologies to perform molecular screening in the high-risk populations are promising; however, further studies are needed before a translation to clinical practice, namely regarding sample collection in this hard to reach population.
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![**A)** Differences of entropy observed among CNA results for the genes analyzed in the OSCC tumor and non-tumor tissue samples. **B)** Copy number gains and losses detected in tumor and non-tumor tissue samples of cluster 1 and cluster 2. Loss is represented by red and gain by blue.](jcav09p1885g002){#F2}
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![Kaplan-Meier curves for the two clusters identified in the joint database (our and validation cohorts) and the distribution of patients\' age in both clusters, **A)** for tumor stage I+II, **B)** for tumor stage III+IV. Cluster 1 is represented by 1 and cluster 2 by 2.](jcav09p1885g004){#F4}

![**A)** Differences of entropy observed among methylation status for the analyzed genes in the OSCC tumor and non-tumor tissue samples, **B)** Methylation profile detected in tumor and non-tumor tissue samples of our cohort for the cluster 1 and the cluster 2.](jcav09p1885g005){#F5}
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![Importance level of the genes analyzed to discriminate between the patients that develop or not metastases/relapses**, A)** using CNA data,**B)** using gene promoter methylation genes.](jcav09p1885g007){#F7}

![Agreement measured by Kappa value between tumor tissue and scrapped cells. **A)** using CNAs, **B)** using methylation status.](jcav09p1885g008){#F8}

###### 

Clinical-pathologic characteristics of study population

  Patients (n=49)                                                           
  ------------------------ --------- -------------------------------------- ---------
                           n (%)                                            n (%)
  Gender                             Age at diagnosis (Years)               
  **Male**                 39 (80)   **\<60**                               24 (49)
  **Female**               10 (20)   **≥60**                                25 (51)
  Anatomic Subsite                   Invasion peri(neural)                  
  **Tongue**               26 (53)   **Yes**                                26 (53)
  **Floor of the mouth**   12 (25)   **No**                                 20 (41)
  **Retromolar Trigone**   4 (8)     NA                                     3 (6)
  **Jugal Mucosa**         2 (4)     Differentiation                        
  **Palate**               2 (4)     **Well**                               38 (78)
  **Alveolar ridge**       3 (6)     **Moderate**                           9 (18)
  Tobacco                            **Poor**                               1 (2)
  **Yes**                  31 (63)   **NA**                                 1 (2)
  **No**                   15 (31)   Margins                                
  NA                       3 (6)     **R0**                                 29 (59)
  Alcohol                            **R1**                                 16 (33)
  **Yes**                  29 (59)   **NA**                                 4 (8)
  **No**                   15 (31)   HPV                                    
  NA                       5 (10)    **Positive**                           1 (2)
  TNM stage                          **Negative**                           48 (98)
  **I**                    9 (18)    Vital status                           
  **II**                   14 (29)   **Relapses/Metastasis in follow-up**   16 (33)
  **III**                  7 (14)    **Dead - OSCC**                        14 (29)
  **IV**                   19 (39)   **Dead-non-OSCC**                      1 (2)
  Treatment                                                                 
  **surgery alone**        13 (27)                                          
  **Surgery + RT**         26 (53)                                          
  **Surgery + RT + QT**    6 (12)                                           
  **NA**                   4 (8)                                            

NA- Not Available; RT - Radiotherapy; QT - Chemotherapy

###### 

Clinical-pathologic characteristics of validation cohort from TCGA

  Patients (n=314)                                                                     
  -------------------------------- ------------ -------------------------------------- ------------
                                   n (%)                                               n (%)
  Gender                                        Age at diagnosis (Years)               
  **Male**                         209 (67)     **\<60**                               133(42.4)
  **Female**                       105 (33)     **≥60**                                180(57.3)
  Anatomic Subsite                              Invasion peri(neural)                  
  **Tongue**                       131 (42)     **Yes**                                134(42.7)
  **Oral cavity**                  73 (23)      **No**                                 113(36)
  **Floor of the mouth**           63(20)       NA                                     63(20.1)
  **Buccal Mucosa**                22(7)        Margins                                
  **Alveolar Ridge**               18 (6)       **R0**                                 229(72.9)
  **Hard Palate**                  7 (2)        **R1**                                 37(11.8)
  Tobacco                                       **Close**                              34(10.8)
  **Yes**                          215 (68.5)   **NA**                                 14(4.5)
  **No**                           90 (28.6)    HPV                                    
  NA                               9 (2.9)      **Positive**                           32 (10.2)
  Alcohol                                       **Negative**                           281 (89.5)
  **Yes**                          203 (64,6)   **NA**                                 1 (0.3)
  **No**                           104 (33,1)   Country                                
  NA                               7 (2,3)      **United States**                      212 (67)
  TNM stage                                     **Canada**                             37(11.8)
  **I**                            12 (3.8)     **Brazil**                             10(3.2)
  **II**                           76 (24.2)    **Poland**                             9(2.9)
  **III**                          63 (20)      **Other**                              9(2.9)
  **IV**                           155 (49.4)   **NA**                                 37(11.8)
  **NA**                           8 (2.5)      Vital status                           
  Treatment                                     **Relapses/Metastasis in follow-up**   189(60.2)
  **QT**                           82(26.1)                                            
  **Immunotherapy**                2(0.6)                                              
  **Targeted Molecular Therapy**   1(0.3)                                              
  **NA**                           229(72.9)                                           

NA- Not Available; RT - Radiotherapy; QT - Chemotherapy
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